1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Fragile X Syndrome (FXS) - Epidemiology Forecast - 2030

Fragile X Syndrome (FXS) - Epidemiology Forecast - 2030

  • July 2020
  • 100 pages
  • ID: 5921862
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Fragile X Syndrome (FXS)—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Fragile X Syndrome (FXS) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Fragile X Syndrome (FXS) Understanding
Fragile X Syndrome is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3. It leads to a hyper-methylated region in the gene promoter, therefore, silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation.
It is considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome. At birth, Fragile X Syndrome neonates often exhibit no clinical signs of Fragile X Syndrome with most parameters (e.g., head circumference, weight, and height) in the normal range. In early childhood Fragile X Syndrome, physical and developmental features become more apparent, including developmental delays, psychomotor delays, intellectual disabilities, and a long face with prominent ears and flat feet. Along with biting, hand flapping, poor eye contact, language disorders from disorganized speech to complete lack of speech depending on phenotype severity can also be observed.

<>Fragile X Syndrome (FXS) Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalence of Fragile X Syndrome in 7MM, Gender-specific Diagnosed Prevalence of Fragile X Syndrome in 7MM, Age-specific Diagnosed Prevalence of Fragile X Syndrome in 7MM, the scenario of Fragile X Syndrome (FXS) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

<>Fragile X Syndrome (FXS) Detailed Epidemiology Segmentation
• The prevalent population of Fragile X Syndrome in 7MM is expected to increase at a CAGR of 0.62% for the study period, i.e. 2017–2030.
• Among the Gender-specific prevalent cases, in 2017, there were 40,102 cases of Fragile X Syndrome (FXS) in males and 27,552 cases in females, in the US.
• The United States accounts for the highest diagnosed prevalent cases of Fragile X Syndrome with 67,654 cases in 2017

Scope of the Report
• The report covers the descriptive overview of Fragile X Syndrome (FXS), explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Fragile X Syndrome (FXS).
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Fragile X Syndrome (FXS), Total Diagnosed and Treated Cases of Fragile X Syndrome (FXS).

Report Highlights
• 11-year Forecast of Fragile X Syndrome (FXS)
• 7MM Coverage
• Total Diagnosed Prevalence of Fragile X Syndrome (FXS)
• Gender-specific Prevalence of Fragile X Syndrome (FXS)
• Age-specific Prevalence of Fragile X Syndrome (FXS)
• The total diagnosed prevalent population of FXS in the 7MM is expected increase at a CAGR of 0.62%.
• The United States contributed to the largest diagnosed prevalent-patient share acquiring ~57.35% of the total 7MM share in 2017

Key Questions Answered
• What is the disease risk, burden and unmet needs of Fragile X Syndrome (FXS)?
• What is the historical Fragile X Syndrome (FXS) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Fragile X Syndrome (FXS) at the 7MM level?
• What will be the growth opportunities across the 7MM concerning the patient population pertaining to Fragile X Syndrome (FXS)?
• Out of the countries mentioned above, which country would have the highest prevalent population of Fragile X Syndrome (FXS) during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Reasons to buy
The Fragile X Syndrome (FXS) report will allow the user to:
• Develop business strategies by understanding the trends shaping and driving the 7MM Fragile X Syndrome (FXS) market.
• Quantify patient populations in the 7MM Fragile X Syndrome (FXS) market to improve product design, pricing, and launch plans.
• The Fragile X Syndrome (FXS) epidemiology report and model are written and developed by Masters and PhD level epidemiologists.
• The Fragile X Syndrome (FXS) epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments

<>• Patient Segmentation
• Disease Risk and Burden

<>• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

HER2-Positive Breast Cancer - Epidemiology Forecast to 2030

  • $ 3995
  • August 2021
  • 61 pages

HER2-Positive Breast Cancer - Epidemiology Forecast to 2030 Summary Breast cancer is the second most common cancer in the world and the most common cancer in women worldwide, accounting for 25.2% of all ...

  • United States
  • United Kingdom
  • Breast Cancer
  • Epidemiology
  • Industry analysis
  • Cancer Incidence
  • Overweight Prevalence

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on